CanSino Biologics Inc. (CASBF)

Overview

CanSino Biologics Inc., established in 2009 and based in Tianjin, the People's Republic of China, is at the forefront of developing, manufacturing, and commercializing vaccines. The company primarily focuses on innovations in the field of vaccine research to combat various infectious diseases, including the novel coronavirus. Their dedication to advancing vaccine technology underscores their commitment to addressing global public health challenges.

Products and Services

• Convidecia and the Ad5-nCoV for Inhalation: Vaccines targeting the recombinant novel coronavirus disease. These vaccines represent CanSino's response to the COVID-19 pandemic, highlighting their notable contributions to global vaccine development efforts against this unprecedented health crisis.
• Ad5-EBOV: An Ebola virus vaccine, indicating CanSino's involvement in combating other critical viral threats. This vaccine underlines the company's broader focus beyond COVID-19, addressing diseases with significant mortality rates and global health implications.
• MCV2 and MCV4: Vaccines for the prevention of N. meningitides, a cause of meningitis. This showcases CanSino's dedication to protecting against bacterial diseases that can lead to severe neurological damage or death, especially in children and adolescents.
• DTcP vaccine for infants and DTcP Booster: Currently in Phase I clinical trial, these vaccines aim at providing a solution for the weaker protection against pertussis (whooping cough) following primary vaccination. This represents an important step in infant and childhood disease prevention.
• Tdcp Adolescent and Adult vaccine: Targets the treatment of pertussis (whooping cough) in older demographics, highlighting the company's comprehensive approach to vaccine development across age groups.
• PBPV: A serotype-independent protein-based pneumococcal vaccine currently in Phase I clinical trials. This innovative approach could potentially offer a broader protection against pneumococcal diseases compared to the existing vaccines.
• PCV13i: A pneumococcal conjugate vaccine, also in Phase I clinical trial, aimed at preventing pneumococcal diseases, which can lead to severe infections such as pneumonia, meningitis, and sepsis.
• TB Booster: Aimed at the BCG-vaccinated population, this vaccine is in Phase I clinical trial and represents a novel approach towards tuberculosis prevention, a disease with a significant global burden.
• Preclinical stage products: This includes a diverse range of vaccines in development, such as the DTcP-Hib Combo vaccine for diphtheria, tetanus, pertussis, and Haemophilus influenzae type b; CS-2023 for meningitis; CS-2028 for a multivalent conjugate vaccine; CS-2032 for shingles; CS-2036 for polio; CS-2047 for tetanus; and CS-2201 DTcP for a combination vaccine. These preclinical projects demonstrate CanSino's ambitious research and development pipeline aimed at addressing a wide array of infectious diseases.